Advertisement

Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate.

S Chouaib, R J Robb, K Welte, and B Dupont

Find articles by Chouaib, S. in: JCI | PubMed | Google Scholar

Find articles by Robb, R. in: JCI | PubMed | Google Scholar

Find articles by Welte, K. in: JCI | PubMed | Google Scholar

Find articles by Dupont, B. in: JCI | PubMed | Google Scholar

First published August 1, 1987 - More info

Published in Volume 80, Issue 2 (August 1, 1987)
J Clin Invest. 1987;80(2):333–340. doi:10.1172/JCI113077.
Copyright © 1987, The American Society for Clinical Investigation.
Published August 1, 1987

Research Article

Abstract

We have investigated the inhibitory potential of prostaglandin E2 (PGE2) with respect to intracellular messengers implicated in the signaling system of T-lymphocyte activation pathway. Using the fluorescent indicator Quin 2, it is demonstrated that PGE2 inhibits the increase in cytosolic-free calcium concentration [Ca2+]i. Reconstitution of calcium mobilization in the presence of PGE2 by the calcium ionophore A23187 results in a partial restoration of both interleukin 2 (IL2) production and cell proliferation and has no effect on the inhibition of transferrin receptor expression. In contrast, the treatment of cell cultures with the tumor promotor 12.0 tetra decanoyl phorbol-13-acetate (TPA) abrogates the suppressor activity of PGE2. When T lymphocyte stimulation is provided by the combination of A23187 and TPA, the PGE2 inhibitory effect does not occur. These data also indicate that the down regulation of transferrin receptor by PGE2 is proximal to protein kinase C activation and is not associated with decreased expression of the functional IL2 receptor.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Revision history
  • Version 1 (June 26, 2014): No description
Advertisement
Advertisement